Multiple Pharmaceutical Companies Announce Executive Leadership Changes Since April

　　【Pharmaceutical Station: Industry Dynamics] Currently, the transformation in the pharmaceutical industry is gradually being reflected in every enterprise and among every mid-to-senior level manager. Since April, another wave of personnel changes has occurred among executives at pharmaceutical companies.
 

Lingrui Pharmaceutical Chairman Resigns
 

On April 26, Lingrui Pharmaceutical issued an announcement stating that the Company’s Board of Directors received a resignation letter from Mr. Cheng Jianjun, Chairman of the Board, on April 25, 2019. Due to personal reasons, Mr. Cheng Jianjun has applied to resign from his position as Chairman of the Seventh Session of the Board of Directors. Following his resignation as Chairman, Mr. Cheng Jianjun will continue to serve as a Director of the Seventh Session of the Board of Directors.
 

Resignations of the General Manager, Chief Financial Officer, and Securities Affairs Representative of Changjiang Runfa
 

Changjiang Runfa recently announced that its Board of Directors received written resignation reports from Mr. Qiu Qiqin, Mr. Lu Bin, and Mr. Qiu Jiajun on April 23, 2019. Mr. Qiu Qiqin resigned from his position as General Manager due to a shift in his personal work focus; Mr. Lu Bin resigned from his position as Chief Financial Officer due to a shift in his personal work focus; and Mr. Qiu Jiajun resigned from his position as Securities Affairs Representative due to adjustments in his work arrangements.
 

In addition, the Board of Directors approved the appointment of Mr. Lu Yifeng as General Manager, Mr. Li Yiqing as Deputy General Manager, Mr. Zhang Yi as Chief Financial Officer, and Mr. Sun Wenyao as Securities Affairs Representative of the Company.
 

Yabao Pharmaceutical General Manager and Board Secretary Resign
 

Recently, Yabao Pharmaceutical Group Co., Ltd. announced that its Board of Directors had received written resignation reports from Mr. Ren Wuxian, the Company’s General Manager, and Mr. Wang Gang, the Board Secretary. Mr. Ren has resigned from his position as General Manager due to personal reasons but will continue to serve as Chairman of the Board. Mr. Wang has resigned from his position as Board Secretary due to personal reasons and will no longer hold any positions within the Company following his resignation.
 

Resignation of Director and Financial Controller of Zhongjia Pharmaceutical
 

Zhongjia Pharmaceutical recently announced that the Board of Directors received the resignation report from Zhang Lijun, Director and Chief Financial Officer, on April 17, 2019, with the resignation taking effect on April 19, 2019. Following his resignation, Mr. Zhang will no longer hold any other positions within the company.
 

In addition, prior to the election of new directors, the resigning director, Zhang Lijun, shall continue to perform his duties as a director.
 

　Hainan Haiyao Vice Chairman and Deputy General Manager Resigns
 

Hainan Haiyao announced that on April 22, 2019, the Board of Directors of Hainan Haiyao received written resignation reports submitted by Ren Rongbo, Vice Chairman of the Board; Li Xuezhong, Deputy General Manager; and Wang Jianpeng, Deputy General Manager. Following their resignations, Ren Rongbo, Li Xuezhong, and Wang Jianpeng no longer hold any positions within the company.
 

Chairman of Jinghua Pharmaceutical Resigns
 

On April 23, Jinghua Pharmaceutical announced that the Board of Directors had received a written resignation letter from Zhu Chunlin on April 22, 2019. Due to personal health and age-related reasons, Zhu Chunlin resigned as Chairman of the Company’s Board of Directors, and simultaneously stepped down from his positions as a member of the Nomination Committee, Audit Committee, and Strategy Committee of the Fourth Session of the Board of Directors.
 

Roche Pharma Vice President of Market Access and Channel Management Resigns
 

On April 12, Roche Pharma China announced that Mr. Chen Wende, former Vice President of Corporate Affairs and Market Access & Channel Management at Roche Pharma China, will officially leave Roche on May 10 to pursue external development opportunities. His successor is Ms. Bian Xin, who recently stepped down as Chief Commercial Officer at BeOne Medicines.
 

　　GSK’s Current Vice President Resigns
 

On April 4, GSK announced that Gao Song, current Vice President and Head of the Respiratory Business Unit, will leave GSK at the end of April.
 

　Haisco Pharmaceutical: Director and Chairman of the Supervisory Board Resigns
 

On April 10, Haisco Pharmaceutical Group Co., Ltd. released two announcements regarding personnel changes. The announcements stated that the Board of Directors had received a written resignation report from Mr. Wang Xuemin. Due to personal reasons, Mr. Wang Xuemin applied to resign from his position as a director of the third session of the Board of Directors of the company and will no longer hold any positions within the company after his resignation; Ms. Liu Hanbing, Chairperson of the Supervisory Committee of Haisco, applied to resign from her position as supervisor/chairperson of the third session of the Supervisory Committee of the company but will continue to serve as the Human Resources Director of the company after her resignation.